HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has maintained a Buy rating on Fulcrum Therapeutics (NASDAQ:FULC) and increased the price target from $14 to $17.

February 28, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Fulcrum Therapeutics and raises the price target from $14 to $17.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100